PFE-N
ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.
ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.
It is still very cheap in his opinion. It is cheaper than the market multiple. It is growing revenue, earnings and dividends as well as buying back stock. About a 4% dividend yield. A great management team. They merged their consumer business with GSK-N. There should be a boost to the share price when this gets IPOed in two to three years. In the near term there is their generic drug business that is merging with MYL-Q. They will then be an innovation-focused and higher growth R&D kind of Pfizer. (Analysts’ price target is $41.80)
It is still very cheap in his opinion. It is cheaper than the market multiple. It is growing revenue, earnings and dividends as well as buying back stock. About a 4% dividend yield. A great management team. They merged their consumer business with GSK-N. There should be a boost to the share price when this gets IPOed in two to three years. In the near term there is their generic drug business that is merging with MYL-Q. They will then be an innovation-focused and higher growth R&D kind of Pfizer. (Analysts’ price target is $41.80)
He was concerned that GSK was getting more growth focused. They spun off their consumer products with Novartis, giving up their oncology department. Now they have a joint venture with Pfizer. Having it as a longterm asset is probably positive.
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 5
Neutral - Hold Signals / Votes : 3
Bearish - Sell Signals / Votes : 8
Total Signals / Votes : 16
Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N
In the last year, 16 stock analysts published opinions about PFE-N. 5 analysts recommended to BUY the stock. 8 analysts recommended to SELL the stock. The latest stock analyst recommendation is DON'T BUY. Read the latest stock experts' ratings for Pfizer Inc.
Pfizer Inc was recommended as a Top Pick by Stan Wong on 2020-07-09. Read the latest stock experts ratings for Pfizer Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
16 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.
On 2020-07-10, Pfizer Inc (PFE-N) stock closed at a price of $33.83.
